Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK3 | O43293 | 8/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791976 | 1.00 | DAPK3 (0.61) | DAPK3GAALMNAALOX5NOTUM | |
| SCHEMBL24763255 | 0.88 | DAPK3 (0.67) | DAPK3GAALMNAALOX5NOTUM | |
| SCHEMBL9464880 | 0.88 | DAPK3 (0.69) | DAPK3GAALMNAALOX5NOTUM | |
| SCHEMBL9464883 | 0.88 | DAPK3 (0.69) | DAPK3GAALMNAALOX5NOTUM | |
| SCHEMBL9464738 | 0.81 | DAPK3 (0.75) | DAPK3GAAALOX5NOTUMSMN1; SMN2 | |
| SCHEMBL9464734 | 0.81 | DAPK3 (0.75) | DAPK3GAAALOX5NOTUMSMN1; SMN2 | |
| SCHEMBL24763129 | 0.81 | ALOX5 (0.59) | DAPK3GAALMNAALOX5NOTUM | |
| SCHEMBL6795692 | 0.79 | DAPK3 (0.73) | DAPK3GAAALOX5NOTUMSMN1; SMN2 | |
| SCHEMBL6795695 | 0.79 | DAPK3 (0.73) | DAPK3GAAALOX5NOTUMSMN1; SMN2 | |
| SCHEMBL24418241 | 0.79 | PLCG2 (0.68) | DAPK3GAALMNAALOX5NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180943-A1 | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis | WARNER-LAMBERT COMPANY LLC | 2004-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180943-A1 | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis | APP, PSEN1, PSEN2 | DAPK3 1049/4885GAA 74/4885LMNA 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.